Patent search ap:("Merck Sharp & Dohme Corp.") AND inv:"Ping Chen" Page 1

1.

发明授权
Crystalline forms of a dipeptidyl peptidase-IV inhibitors 有权
Title translation: 二肽基肽酶-IV抑制剂的结晶形式

公开(公告)号：US09181262B2

公开(公告)日：2015-11-10

申请号：US14507001

申请日：2014-10-06

Applicant: Merck Sharp & Dohme Corp , Merck Sharp & Dohme Ltd.

Inventor： Itzia Z. Arroyo , Davida Krueger , Ping Chen , Aaron J. Moment , Tesfaye Biftu , Faye Sheen , Yanfeng Zhang

IPC: C07D487/04 , A61K31/4162 , A61K31/4439 , A61K31/4985 , A61K31/513

CPC classification number: C07D487/04 , A61K31/4162 , A61K31/4439 , A61K31/4985 , A61K31/513 , C07B2200/13 , Y02P20/55

Abstract: Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

Abstract translation: （2R，3S，5R）-2-（2,5-二氟苯基）-5- [2-（甲基磺酰基）-2,6-二氢吡咯并[3,4-c]吡唑-5（4H） - 吡啶-3-基]四氢-2H-吡喃-3-胺是二肽基肽酶-IV的有效抑制剂，可用于治疗非胰岛素依赖型（2型）糖尿病。本发明还涉及含有这些新型形式的药物组合物，制备这些形式的方法及其药物组合物及其用于治疗2型糖尿病的用途。

2.

发明申请
NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES 有权
Title translation: 新型亚氨基二咪唑六氢呋喃[E，2-B]呋喃衍生物

公开(公告)号：US20150284411A1

公开(公告)日：2015-10-08

申请号：US14419774

申请日：2013-08-19

Applicant: James M. APGAR , Ashok ARASAPPAN , Tesfaye BIFTU , Ping CHEN , Danqing FENG , Erin GUIDRY , Jacqueline HICKS , Ahmet KEKEC , Kenneth LEAVITT , Bing LI , Troy MCCRACKEN , Iyassu SEBHAT , Xiaoxia QIAN , Lan WEI , Robert WILKENING , Zhicai WU , Merck Sharp & Dohme Corp.

Inventor： James M. Apgar , Ashok Arasappan , Tesfaye Biftu , Ping Chen , Danqing Feng , Erin Guidry , Jacqueline D. Hicks , Ahmet Kekec , Kenneth J. Leavitt , Bing Li , Troy McCracken , Iyassu Sebhat , Xiaoxia Qian , Lan Wei , Robert R. Wilkening , Zhicai Wu

IPC: C07D519/00 , A61K31/438 , A61K45/06 , A61K31/501 , A61K31/5377 , A61K31/541 , A61K31/437 , A61K31/506

CPC classification number: C07D519/00 , A61K31/366 , A61K31/397 , A61K31/437 , A61K31/438 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06 , A61K2300/00

Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Abstract translation: 结构式（I）的新型化合物是AMP-蛋白激酶的活化剂，可用于治疗，预防和抑制AMPK活化蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病，高血糖症，代谢综合征，肥胖症，高胆固醇血症和高血压。

3.

发明申请
HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS 有权

公开(公告)号：US20230018413A1

公开(公告)日：2023-01-19

申请号：US17632065

申请日：2020-08-03

Applicant: Merck Sharp & Dohme Corp.

Inventor： Stephane L. Bogen , Ping Chen , Dane James Clausen , Jinsong Hao , Dipannita Kalyani , Michael T. Rudd , Shawn P. Walsh , Lan Wei , Dexi Yang

IPC: C07D403/04 , C07D207/14 , C07D401/04 , C07D471/04 , C07D417/04 , C07D413/10 , C07D417/14 , C07D413/04 , C07D409/04 , C07D405/04 , C07D498/04 , C07D491/048

Abstract: The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

4.

发明申请
Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors 有权

公开(公告)号：US20210393600A1

公开(公告)日：2021-12-23

申请号：US17047247

申请日：2019-04-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： Liangqin Guo , Hongjun Zhang , Ping Chen , Dane Clausen , Xavier Fradera , Yongxin Han , Shuwen He , Xianhai Huang , Alexander Pasternak , Qinglin Pu , Li Xiao , Feng Ye

IPC: A61K31/44 , A61K45/06 , C07C237/22 , C07C255/60 , C07D213/75 , C07C271/36 , C07C233/78 , C07C271/24 , C07C233/79 , C07D213/81 , C07D271/06 , C07D239/28 , C07D215/48 , C07C275/30 , C07C275/28 , C07D239/42 , C07D305/06 , C07D261/08 , C07D471/04 , C07D261/20 , C07D209/34 , C07D277/56 , C07D217/02 , C07D231/14 , C07D237/28 , C07D241/24 , C07D217/26 , A61K31/167 , A61K31/27 , A61K31/4245 , A61K31/47 , A61K31/17 , A61K31/505 , A61K31/337 , A61K31/437 , A61K31/42 , A61K31/426 , A61K31/472 , A61K31/415 , A61K31/4965

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

5.

发明授权
Benzimidazole tetrahydropyran derivatives 有权
Title translation: 苯并咪唑四氢吡喃衍生物

公开(公告)号：US09527839B2

公开(公告)日：2016-12-27

申请号：US14420090

申请日：2013-08-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： James M. Apgar , Tesfaye Biftu , Ping Chen , Danqing Feng , Jacqueline D. Hicks , Ahmet Kekec , Kenneth J. Leavitt , Bing Li , Iyassu Sebhat , Xiaoxia Qian , Lan Wei , Robert R. Wilkening , Zhicai Wu

IPC: C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/4184 , A61K31/4196 , A61K31/427 , A61K31/506 , A61K31/5377 , A61K45/06

CPC classification number: C07D417/14 , A61K31/4184 , A61K31/4196 , A61K31/427 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D405/12 , C07D405/14 , C07D413/14

Abstract: Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Abstract translation: 本文所述的新型化合物是AMP-蛋白激酶的活化剂，并且可用于治疗，预防和抑制由AMPK活化的蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病，高血糖症，代谢综合征，肥胖症，高胆固醇血症和高血压。

6.

发明申请
CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权
Title translation: 环状磷酸酯取代的核苷类衍生物及其用于治疗病毒性疾病的方法

公开(公告)号：US20160122380A1

公开(公告)日：2016-05-05

申请号：US14899008

申请日：2014-06-16

Applicant: Merck Sharp & Dohme Corp.

Inventor： Stephane Bogen , Vinay Girijavallabhan , Quang Truong , Ping Chen , Frank Bennett , Angela Kerekes , Qun Dang , David B. Olsen , Ian Davies

IPC: C07H19/10 , A61K45/06 , A61K31/7072

CPC classification number: C07H19/10 , A61K31/661 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K45/06 , C07F9/65586 , C07F9/65744 , C07H19/11 , A61K2300/00

Abstract: The present invention relates to Cyclic Phosphonate Substituted Nucleoside Derivatives of Formula (I): (structure) and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein, as well as to compositions and methods of using the Cyclic Phosphonate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

Abstract translation: 本发明涉及式（I）的环磷酸酯取代的核苷衍生物：（结构）及其药学上可接受的盐，其中B，X，R 1，R 2和R 3如本文所定义，以及使用用于治疗或预防患者HCV感染的环磷酸酯取代的核苷衍生物。

7.

发明申请
NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITORS 审中-公开
Title translation: 脯氨酸-IV抑制剂的新型晶体形式

公开(公告)号：US20150099891A1

公开(公告)日：2015-04-09

申请号：US14507001

申请日：2014-10-06

Applicant: Merck Sharp & Dohme Corp , Merck Sharp & Dohme Ltd.

Inventor： Itzia Z. Arroyo , Davida Krueger , Ping Chen , Aaron J. Moment , Tesfaye Biftu , Faye Sheen , Yanfeng Zhang

IPC: C07D487/04

CPC classification number: C07D487/04 , A61K31/4162 , A61K31/4439 , A61K31/4985 , A61K31/513 , C07B2200/13 , Y02P20/55

Abstract: Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

Abstract translation: （2R，3S，5R）-2-（2,5-二氟苯基）-5- [2-（甲基磺酰基）-2,6-二氢吡咯并[3,4-c]吡唑-5（4H） - 吡啶-3-基]四氢-2H-吡喃-3-胺是二肽基肽酶-IV的有效抑制剂，可用于治疗非胰岛素依赖型（2型）糖尿病。本发明还涉及含有这些新型形式的药物组合物，制备这些形式的方法及其药物组合物及其用于治疗2型糖尿病的用途。

8.

发明授权
Azabenzimidazole tetrahydrofuran derivatives 有权

公开(公告)号：US09868733B2

公开(公告)日：2018-01-16

申请号：US14419825

申请日：2013-08-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： James M. Apgar , Tesfaye Biftu , Ping Chen , Danqing Feng , Jacqueline D. Hicks , Ahmet Kekec , Kenneth J. Leavitt , Bing Li , Iyassu Sebhat , Xiaoxia Qian , Lan Wei , Robert R. Wilkening , Zhicai Wu , Ashok Arasappan

IPC: C07D471/04 , C07D519/00 , A61K31/366 , A61K31/397 , A61K31/4985 , A61K31/19 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/5377 , C07C53/18

CPC classification number: C07D471/04 , A61K31/19 , A61K31/366 , A61K31/397 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5377 , C07C53/18 , C07D519/00 , A61K2300/00

Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.